ImmunoGen‘s patent involves a method to prepare a cell-binding agent-cytotoxic agent conjugate using cysteine-engineered antibodies. The process includes reacting a reducing agent with a capped cell-binding agent and subsequent steps to link the cytotoxic agent. This innovation could lead to new pharmaceutical compositions and treatments. GlobalData’s report on ImmunoGen gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights ImmunoGen Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on ImmunoGen, Nanoparticle drug conjugates was a key innovation area identified from patents. ImmunoGen's grant share as of January 2024 was 45%. Grant share is based on the ratio of number of grants to total number of patents.

Method of preparing cell-binding agent-cytotoxic agent conjugate

Source: United States Patent and Trademark Office (USPTO). Credit: ImmunoGen Inc

A recently granted patent (Publication Number: US11833214B2) discloses a method for preparing a cell-binding agent-cytotoxic agent conjugate, involving a cell-binding agent (CysCBA) with unpaired cysteine residues linked to a cytotoxic agent. The method includes steps such as reacting a reducing agent with a capped cell-binding agent to form a reduced cell-binding agent, followed by reacting it with a selective oxidizing agent to form the CysCBA. The CysCBA is then reacted with a specific compound to create the conjugate.

The patent further details variations in the method, such as the use of different oxidizing agents like dehydroascorbic acid (DHAA), copper sulfate, oxygen, or air, as well as specific reducing agents like TCEP or DPPA. The molar ratio of the reducing agent to the oxidizing agent, the pH range for reactions, and the specific compound formula (I) used in the process are also specified. The method is particularly useful for preparing an antibody-cytotoxic agent conjugate (ADC) for targeted therapy, with the patent providing a detailed formula representation for the final conjugate. This innovative method showcases advancements in the field of conjugate preparation for potential applications in the development of targeted cancer therapies.

To know more about GlobalData’s detailed insights on ImmunoGen, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies